Replimune Group, Inc. (REPL)
5.01
-0.21
(-4.02%)
USD |
NASDAQ |
May 18, 16:00
5.01
0.00 (0.00%)
After-Hours: 20:00
Replimune Group Research and Development Expense (Quarterly) : 52.87M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| REGENXBIO, Inc. | 53.48M |
| Catalyst Pharmaceuticals, Inc. | 2.661M |
| Spyre Therapeutics, Inc. | 60.41M |
| Bristol Myers Squibb Co. | 2.238B |
| ANI Pharmaceuticals, Inc. | 10.60M |